Global Computational Medicine and Drug Discovery Software 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI02240071

Publication Date:

February 28, 2024

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Computational Medicine and Drug Discovery Software market size was valued at US$ million in 2023. With growing demand in downstream market, the Computational Medicine and Drug Discovery Software is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Computational Medicine and Drug Discovery Software market. Computational Medicine and Drug Discovery Software are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Computational Medicine and Drug Discovery Software. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Computational Medicine and Drug Discovery Software market.
Computational Medicine finds its roots in chemistry and quantum mechanics. The foundation of computational medicine is based upon database and constraint-based models.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Key Features:
The report on Computational Medicine and Drug Discovery Software market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Computational Medicine and Drug Discovery Software market. It may include historical data, market segmentation by Type (e.g., Database, Software), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Computational Medicine and Drug Discovery Software market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Computational Medicine and Drug Discovery Software market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Computational Medicine and Drug Discovery Software industry. This include advancements in Computational Medicine and Drug Discovery Software technology, Computational Medicine and Drug Discovery Software new entrants, Computational Medicine and Drug Discovery Software new investment, and other innovations that are shaping the future of Computational Medicine and Drug Discovery Software.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Computational Medicine and Drug Discovery Software market. It includes factors influencing customer ' purchasing decisions, preferences for Computational Medicine and Drug Discovery Software product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Computational Medicine and Drug Discovery Software market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Computational Medicine and Drug Discovery Software market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Computational Medicine and Drug Discovery Software market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Computational Medicine and Drug Discovery Software industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Computational Medicine and Drug Discovery Software market.
麻豆原创 Segmentation:
Computational Medicine and Drug Discovery Software market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Database
Software
Others
Segmentation by application
Computational Physiological Medicine
Drug Discovery And Development
Medical Imaging
Disease Modeling
Predictive Analysis Of Drug Targets
Cellular Simulation
Simulation Software
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Entelos
Genedata
Crown Bioscience
Biognos
Chemical Computing Group
Leadscope
Nimbus Therapeutics
Rhenovia Pharma Limited
Schrodinger
Compugen
Dassault Systemes

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Computational Medicine and Drug Discovery Software 麻豆原创 Size 2019-2030
2.1.2 Computational Medicine and Drug Discovery Software 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Computational Medicine and Drug Discovery Software Segment by Type
2.2.1 Database
2.2.2 Software
2.2.3 Others
2.3 Computational Medicine and Drug Discovery Software 麻豆原创 Size by Type
2.3.1 Computational Medicine and Drug Discovery Software 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Computational Medicine and Drug Discovery Software 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Computational Medicine and Drug Discovery Software Segment by Application
2.4.1 Computational Physiological Medicine
2.4.2 Drug Discovery And Development
2.4.3 Medical Imaging
2.4.4 Disease Modeling
2.4.5 Predictive Analysis Of Drug Targets
2.4.6 Cellular Simulation
2.4.7 Simulation Software
2.5 Computational Medicine and Drug Discovery Software 麻豆原创 Size by Application
2.5.1 Computational Medicine and Drug Discovery Software 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Computational Medicine and Drug Discovery Software 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Computational Medicine and Drug Discovery Software 麻豆原创 Size by Player
3.1 Computational Medicine and Drug Discovery Software 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Computational Medicine and Drug Discovery Software Revenue by Players (2019-2024)
3.1.2 Global Computational Medicine and Drug Discovery Software Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Computational Medicine and Drug Discovery Software Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Computational Medicine and Drug Discovery Software by Regions
4.1 Computational Medicine and Drug Discovery Software 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Computational Medicine and Drug Discovery Software 麻豆原创 Size Growth (2019-2024)
4.3 APAC Computational Medicine and Drug Discovery Software 麻豆原创 Size Growth (2019-2024)
4.4 Europe Computational Medicine and Drug Discovery Software 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Computational Medicine and Drug Discovery Software 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Computational Medicine and Drug Discovery Software 麻豆原创 Size by Country (2019-2024)
5.2 Americas Computational Medicine and Drug Discovery Software 麻豆原创 Size by Type (2019-2024)
5.3 Americas Computational Medicine and Drug Discovery Software 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Computational Medicine and Drug Discovery Software 麻豆原创 Size by Region (2019-2024)
6.2 APAC Computational Medicine and Drug Discovery Software 麻豆原创 Size by Type (2019-2024)
6.3 APAC Computational Medicine and Drug Discovery Software 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Computational Medicine and Drug Discovery Software by Country (2019-2024)
7.2 Europe Computational Medicine and Drug Discovery Software 麻豆原创 Size by Type (2019-2024)
7.3 Europe Computational Medicine and Drug Discovery Software 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Computational Medicine and Drug Discovery Software by Region (2019-2024)
8.2 Middle East & Africa Computational Medicine and Drug Discovery Software 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Computational Medicine and Drug Discovery Software 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.1 Global Computational Medicine and Drug Discovery Software Forecast by Regions (2025-2030)
10.1.1 Global Computational Medicine and Drug Discovery Software Forecast by Regions (2025-2030)
10.1.2 Americas Computational Medicine and Drug Discovery Software Forecast
10.1.3 APAC Computational Medicine and Drug Discovery Software Forecast
10.1.4 Europe Computational Medicine and Drug Discovery Software Forecast
10.1.5 Middle East & Africa Computational Medicine and Drug Discovery Software Forecast
10.2 Americas Computational Medicine and Drug Discovery Software Forecast by Country (2025-2030)
10.2.1 United States Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.2.2 Canada Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.2.3 Mexico Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.2.4 Brazil Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3 APAC Computational Medicine and Drug Discovery Software Forecast by Region (2025-2030)
10.3.1 China Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3.2 Japan Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3.3 Korea Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3.4 Southeast Asia Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3.5 India Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.3.6 Australia Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.4 Europe Computational Medicine and Drug Discovery Software Forecast by Country (2025-2030)
10.4.1 Germany Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.4.2 France Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.4.3 UK Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.4.4 Italy Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.4.5 Russia Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.5 Middle East & Africa Computational Medicine and Drug Discovery Software Forecast by Region (2025-2030)
10.5.1 Egypt Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.5.2 South Africa Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.5.3 Israel Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.5.4 Turkey Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.5.5 GCC Countries Computational Medicine and Drug Discovery Software 麻豆原创 Forecast
10.6 Global Computational Medicine and Drug Discovery Software Forecast by Type (2025-2030)
10.7 Global Computational Medicine and Drug Discovery Software Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Entelos
11.1.1 Entelos Company Information
11.1.2 Entelos Computational Medicine and Drug Discovery Software Product Offered
11.1.3 Entelos Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Entelos Main Business Overview
11.1.5 Entelos Latest Developments
11.2 Genedata
11.2.1 Genedata Company Information
11.2.2 Genedata Computational Medicine and Drug Discovery Software Product Offered
11.2.3 Genedata Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Genedata Main Business Overview
11.2.5 Genedata Latest Developments
11.3 Crown Bioscience
11.3.1 Crown Bioscience Company Information
11.3.2 Crown Bioscience Computational Medicine and Drug Discovery Software Product Offered
11.3.3 Crown Bioscience Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Crown Bioscience Main Business Overview
11.3.5 Crown Bioscience Latest Developments
11.4 Biognos
11.4.1 Biognos Company Information
11.4.2 Biognos Computational Medicine and Drug Discovery Software Product Offered
11.4.3 Biognos Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Biognos Main Business Overview
11.4.5 Biognos Latest Developments
11.5 Chemical Computing Group
11.5.1 Chemical Computing Group Company Information
11.5.2 Chemical Computing Group Computational Medicine and Drug Discovery Software Product Offered
11.5.3 Chemical Computing Group Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Chemical Computing Group Main Business Overview
11.5.5 Chemical Computing Group Latest Developments
11.6 Leadscope
11.6.1 Leadscope Company Information
11.6.2 Leadscope Computational Medicine and Drug Discovery Software Product Offered
11.6.3 Leadscope Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Leadscope Main Business Overview
11.6.5 Leadscope Latest Developments
11.7 Nimbus Therapeutics
11.7.1 Nimbus Therapeutics Company Information
11.7.2 Nimbus Therapeutics Computational Medicine and Drug Discovery Software Product Offered
11.7.3 Nimbus Therapeutics Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Nimbus Therapeutics Main Business Overview
11.7.5 Nimbus Therapeutics Latest Developments
11.8 Rhenovia Pharma Limited
11.8.1 Rhenovia Pharma Limited Company Information
11.8.2 Rhenovia Pharma Limited Computational Medicine and Drug Discovery Software Product Offered
11.8.3 Rhenovia Pharma Limited Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Rhenovia Pharma Limited Main Business Overview
11.8.5 Rhenovia Pharma Limited Latest Developments
11.9 Schrodinger
11.9.1 Schrodinger Company Information
11.9.2 Schrodinger Computational Medicine and Drug Discovery Software Product Offered
11.9.3 Schrodinger Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Schrodinger Main Business Overview
11.9.5 Schrodinger Latest Developments
11.10 Compugen
11.10.1 Compugen Company Information
11.10.2 Compugen Computational Medicine and Drug Discovery Software Product Offered
11.10.3 Compugen Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Compugen Main Business Overview
11.10.5 Compugen Latest Developments
11.11 Dassault Systemes
11.11.1 Dassault Systemes Company Information
11.11.2 Dassault Systemes Computational Medicine and Drug Discovery Software Product Offered
11.11.3 Dassault Systemes Computational Medicine and Drug Discovery Software Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Dassault Systemes Main Business Overview
11.11.5 Dassault Systemes Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.